Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Bispecific antibodies targeting the T cell receptor (TCR)/CD3 complex and tumor antigens can redirect cytotoxic T lymphocytes (CTLs) against cancer cells.
• High-affinity binding to CD3 might impair T cell stimulation and lead to in vivo T cell targeting over tumor targeting.

Purpose of the Study:

• To investigate the impact of CD3 binding affinity on the efficacy of bispecific single-chain antibodies (BscAbs) for cancer immunotherapy.
• To generate and evaluate BscAb variants with modulated affinity for the human CD3 complex.

Main Methods:

• Site-directed mutagenesis was employed to create BscAb variants with altered binding affinities to CD3.
• The functional activity of BscAb variants was assessed by measuring T cell activation and cytotoxicity against EpCAM-expressing tumor cells.
• TCR serial triggering model was utilized to interpret the observed results.

Main Results:

• A BscAb mutant with increased CD3 binding affinity exhibited reduced efficacy in targeting T cells against EpCAM+ tumors.
• BscAb variants with decreased CD3 binding affinity demonstrated efficient T cell activation and cytotoxicity, particularly at low tumor cell densities.
• Rapid dissociation of low-affinity BscAbs correlated with enhanced therapeutic potential.

Conclusions:

• Optimizing CD3 binding affinity is crucial for the efficacy of bispecific antibodies in cancer immunotherapy.
• BscAbs with very low affinity for the TCR-CD3 complex show promise for preferential tumor cell localization and enhanced therapeutic outcomes.
• These findings support the TCR serial triggering model and suggest a novel strategy for designing effective bispecific immunotherapies.